SEATTLE--(BUSINESS WIRE)--Acucela Inc. (TOKYO:4589), a clinical-stage biotechnology company that specializes in discovering and developing novel drug candidates to potentially treat and slow the progression of sight-threatening ophthalmic diseases, today announced that it has filed an opposition to the motion to compel a special shareholders meeting filed in Washington state court by SBI Holdings, Inc. and certain of its affiliates (collectively, “SBI”), and Ryo Kubota, MD, PhD, Acucela’s founder and Chairman. As previously disclosed, on March 2, 2015 (Pacific Standard Time), SBI and Dr. Kubota filed a lawsuit in Washington state court seeking to compel the Company to hold a special shareholders meeting on or before April 28, 2015, and to provide its shareholders written notice of that meeting as soon as practicable but no later than March 31, 2015.
